Voyager Therapeutics (STU:VT6) Construction In Progress : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Construction In Progress?

Voyager Therapeutics Construction In Progress Historical Data

The historical data trend for Voyager Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Construction In Progress Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

1.97

0.71

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Voyager Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Voyager Therapeutics (STU:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines